Myriva Quinolones

Moxifloxacin is a fourth generation fluoroquinolone: an inhibitor of bacterial topoisomerase IV and DNA gyrase with expanded activity against gram-positive bacteria as well as atypical pathogens. 

Myriva

Myriva Moxifloxacin (as HCL) 400 mg

  • Dosage and administration

    Adults

    Type of Infection

    Dose Every 24 hours

    Duration (days)

    Community Acquired Pneumonia

    400 mg

    10

    Complicated Skin and Skin Structure Infections (SSSI)

    400 mg

    7–21

    Pelvic Inflammatory Disease

    400 mg

    14

    Acute Bacterial Sinusitis

    400 mg

    7

    Acute Exacerbation of Chronic Bronchitis

    400 mg

    5-10

     Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established

  • Contraindications
    • Hypersensitivity to moxifloxacin, other quinolones or to any of the excipients.
    • Pregnancy and lactation
    • Patients below 18 years of age.
    • Patients with a history of tendon disease/disorder related to quinolone treatment.
    • Congenital or documented acquired QT prolongation
    • Electrolyte disturbances, particularly in uncorrected hypokalaemia
    • Clinically relevant bradycardia
    • Clinically relevant heart failure with reduced left-ventricular ejection fraction
    • Previous history of symptomatic arrhythmias
    • Moxifloxacin should not be used concurrently with other drugs that prolong the QT interval.
    • Patients with impaired liver function.